Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer
Yasutoshi Kuboki, Satoshi Yamashita, Tohru Niwa et al. · Annals of Oncology · 2015
Cited by 81 works. doi:10.1093/annonc/mdv508 Open-access PDF
Authors
- Yasutoshi Kuboki
- Satoshi Yamashita
- Tohru Niwa
- Toshikazu Ushijima
- Akiko Kawano Nagatsuma
- Takeshi Kuwata
- Takayuki Yoshino
- Toshihiko Doi
- Atsushi Ochiai
- Atsushi Ohtsu
References
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Comprehensive molecular characterization of gastric adenocarcinoma
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial